Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Targeting the HuR oncogenic role with a new class of cytoplasmic dimerization inhibitors.Cancer Research2021
2020 Elavl1 role in cell fusion and tunneling membrane nanotube formations with implication to treat glioma heterogeneityCancers.  12:1-18. 2020
2020 Seven-Year Experience from the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical TrialsJAMA Neurology.  77:755-763. 2020
2020 Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): Results of a double-blind randomized phase II trialClinical Cancer Research.  26:1586-1594. 2020
2020 Glioma risk associated with extent of estimated European genetic ancestry in African Americans and HispanicsInternational Journal of Cancer.  146:739-748. 2020
2020 An update on neurofibromatosis type 1-associated gliomasCancers.  12. 2020
2019 Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cellsCancer Biology and Therapy.  20:979-988. 2019
2019 An early feasibility study of the Nativis Voyager ® device in patients with recurrent glioblastoma: first cohort in USCNS Oncology.  8:CNS30. 2019
2019 MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trialsClinical Cancer Research.  25:1809-1816. 2019
2019 Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.Clinical Cancer Research.  25:73-79. 2019
2018 Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)Annals of Oncology.  29:viii122-viii123. 2018
2018 Associations of anticoagulant use with outcome in newly diagnosed glioblastomaEuropean journal of cancer.  101:95-104. 2018
2018 Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma 2018
2018 Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastomaCancer Research.  78:3002-3013. 2018
2017 Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyCancer Chemotherapy and Pharmacology.  80:1209-1217. 2017
2017 Hu antigen R (HuR) multimerization contributes to glioma disease progressionJournal of Biological Chemistry.  292:16999-17010. 2017
2017 Older age at the completion of linear growth is associated with an increased risk of adult gliomaCancer Causes and Control.  1-8. 2017
2016 Primary Sellar Rhabdomyosarcoma Arising in Association with a Pituitary AdenomaInternational Journal of Surgical Pathology.  24:753-756. 2016
2016 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)Annals of Oncology.  27:vi103. 2016
2016 Analgesic use and the risk of primary adult brain tumorEuropean Journal of Epidemiology.  31:917-925. 2016
2016 Design of a Phase i Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma 2016
2016 Complications from pharmacotherapyHandbook of Clinical Neurology.  134:235-250. 2016
2015 Ipilimumab-induced encephalopathy with a reversible splenial lesionCancer Immunology Research.  3:598-601. 2015
2015 Growth factor dependent regulation of centrosome function and genomic instability by HuRBiomolecules.  5:263-281. 2015
2015 Brain tumor risk according to germ-line variation in the MLLT10 locusEuropean Journal of Human Genetics.  23:132-134. 2015
2014 Circadian pathway genes in relation to glioma risk and outcomeCancer Causes and Control.  25:25-32. 2014
2014 The role of Src family kinases in growth and migration of glioma stem cellsInternational Journal of Oncology.  45:302-310. 2014
2013 Toenail iron, genetic determinants of iron status, and the risk of gliomaCancer Causes and Control.  24:2051-2058. 2013
2013 Early life exposures and the risk of adult gliomaEuropean Journal of Epidemiology.  28:753-758. 2013
2013 Anthropometric factors in relation to risk of gliomaCancer Causes and Control.  24:1025-1031. 2013
2013 SWI/SNF gene variants and glioma risk and outcome 2013
2013 A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant gliomaClinical Cancer Research.  19:900-908. 2013
2012 A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)Cancer.  118:5601-5607. 2012
2012 Erratum: An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome (Cancer Causes Control DOI:10.1007/s10552-012-0018-7)Cancer Causes and Control.  23:1745. 2012
2012 Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome functionJournal of Biological Chemistry.  287:32277-32287. 2012
2012 SSBP2 variants are associated with survival in glioblastoma patientsClinical Cancer Research.  18:3154-3162. 2012
2012 An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcomeCancer Causes and Control.  23:1443-1449. 2012
2011 Cilengitide: An RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignanciesFuture Oncology.  7:339-354. 2011
2010 Integrins-a relevant target in glioblastomaEuropean journal of clinical & medical oncology.  2. 2010
2010 Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcomeClinical Cancer Research.  16:2890-2898. 2010
2010 Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United StatesClinical Cancer Research.  16:2443-2449. 2010
2010 A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastomaArchives of Neurology.  67:313-319. 2010
2009 Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR). Implications for impaired post-transcriptional regulation of vascular endothelial growth factorJournal of Biological Chemistry.  284:33989-33998. 2009
2009 Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexateAmerican Journal of Transplantation.  9:1243-1248. 2009
2008 Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiformeExpert Opinion on Investigational Drugs.  17:1225-1235. 2008
2008 Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expressionClinical Cancer Research.  14:4694-4704. 2008
2007 ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesisCancer Biology and Therapy.  6:454-462. 2007
2006 Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy 2006
2006 Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177 2006
2005 Lyn kinase activity is the predominant cellular Src kinase activity in glioblastoma tumor cellsCancer Research.  65:5535-5543. 2005
2005 Treatment of adults with recurrent malignant glioma 2005
2005 IL-1β induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3′ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIARInternational Journal of Cancer.  113:911-919. 2005
2004 Treatment of relapsed central nervous system lymphoma with high-dose methotrexateClinical Cancer Research.  10:5643-5646. 2004
2004 Targeted molecular therapy for malignant gliomasCurrent Treatment Options in Oncology.  5:519-526. 2004
2003 Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuRCancer Research.  63:4181-4187. 2003
2002 Human cytomegalovirus infection and expression in human malignant gliomaCancer Research.  62:3347-3350. 2002
2001 HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAsCancer Research.  61:2154-2161. 2001
2000 Analysis of the 5' end of the mouse Elavl1 (mHuA) gene reveals a transcriptional regulatory element and evidence for conserved genomic organizationGene.  242:125-131. 2000
1999 Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological diseaseJournal of Autoimmunity.  13:435-443. 1999

Chapter

Year Title Altmetric
2012 Primary Melanotic Tumors of the Central Nervous System.  709-714. 2012

Principal Investigator On

  • NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) Collaborative Agreement  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • A Pilot Study of Voraxaze(glucarpidase) in Patients with Central Nervous System Lymphoma  awarded by Memorial Sloan-Kettering Cancer Center 2019 - 2024
  • Brain Tumor Trials Collaborative Agreement  awarded by NIH - National Institutes of Health/DHHS 2019 - 2024
  • Network of Excellence in Neuroscience Clinical Trials (NEXT)  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by AGIOS 2020 - 2022
  • Private Grant  awarded by BIOMIMETIX JV LLC 2019 - 2022
  • GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM  awarded by GLOBAL COALITION FOR ADAPTIVE RESEARCH 2020 - 2022
  • Private Grant  awarded by IN8BIO INC. 2020 - 2022
  • Private Grant  awarded by XCURES, INC 2021 - 2022
  • Cytoplasmic Multimerization of the RNA-Binding Protein HuR is Oncogenic in Glioma  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2014 - 2021
  • Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients  awarded by Johns Hopkins University 2020 - 2021
  • Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas  awarded by Johns Hopkins University 2020 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM  awarded by Johns Hopkins University 2016 - 2021
  • Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)  awarded by Dana-Farber Cancer Institute 2018 - 2021
  • Phase O/I Study of AMG 232 Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters  awarded by Johns Hopkins University 2020 - 2021
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma  awarded by Johns Hopkins University 2018 - 2021
  • A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide  awarded by Johns Hopkins University 2018 - 2021
  • Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2017 - 2021
  • Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL 101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma  awarded by Johns Hopkins University 2017 - 2021
  • Adult Brain Tumor Consortium  awarded by Johns Hopkins University 2014 - 2021
  • Comprehensive Cancer Center Core Support Grant - Neuro-Oncology Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Neuro-Oncology Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations  awarded by Johns Hopkins University 2020 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2021
  • A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or other Primary Brain Tumor  awarded by Johns Hopkins University 2020 - 2021
  • Individualized Screening Trial of Innovative Glioblastoma Therapy (Insight)  awarded by Dana-Farber Cancer Institute 2019 - 2020
  • Phase I Study of MK-1775 with Radiation and Temozolomide In Patients with Newly Diagnosed Glioblastoma and Evaluation of lntratumoral Drug Distribution in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2013 - 2020
  • A Phase I/II Trial of Hydroxychloroquine in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (Therapeutics Studies of Anaplastic Glioma)  awarded by Johns Hopkins University 2011 - 2020
  • Private Grant  awarded by STEMLINE THERAPEUTICS INC 2014 - 2019
  • Private Grant  awarded by NATIVIS, INC. 2015 - 2019
  • Sequence Variation in MtDNA and Extreme Survival in Glioblastoma  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant - Neuro-Oncology Program  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • Private Grant  awarded by ORBUS THERAPEUTICS, INC. 2016 - 2018
  • A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)  awarded by Johns Hopkins University 2013 - 2018
  • Private Grant  awarded by ARCHER BIOSCIENCES 2013 - 2018
  • Phase I/II Study of the Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients with Newly Diagnosed Malignant Glioma  awarded by Johns Hopkins University 2012 - 2018
  • The Effect of IL-7 (CYT107) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide  awarded by Johns Hopkins University 2016 - 2018
  • Refinement and Expansion of the Palliative Care Research Cooperative Group (PCRC)  awarded by Duke University 2017 - 2018
  • Network of Excellence in Neuroscience Clinical Trials (NEXT)  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2011 - 2018
  • Private Grant  awarded by ABBVIE INC 2015 - 2018
  • Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma  awarded by Johns Hopkins University 2016 - 2018
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma (ABTC 1401)  awarded by Johns Hopkins University 2015 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Contemporary Therapeutics for Anaplastic Gliomas - Clinical Trials Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients  awarded by Johns Hopkins University 2014 - 2016
  • Private Grant  awarded by St. Jude Medical 2014 - 2016
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2012 - 2016
  • Private Grant  awarded by ARCHER BIOSCIENCES 2014 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2012 - 2015
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2012 - 2015
  • An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients with Recurrent Glioblastoma Mutiforme  awarded by Johns Hopkins University 2011 - 2014
  • A Phase lb Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2010 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2014
  • Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-ll): A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction  awarded by University of Minnesota 2013 - 2014
  • A Pilot Phase IIB, Randomized, Multi-Center Trial of Argatroban in Combination with Recombinant Tissue Plasminogen Activator for Acute Stroke (ARTSS-2)  awarded by UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER (HOUSTON) 2014
  • N0874: Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma  awarded by Johns Hopkins University 2012 - 2013
  • Private Grant  awarded by EMD SERONO 2009 - 2013
  • Private Grant  awarded by EMD SERONO 2009 - 2013
  • Southeast Region Case-Control Study of Adult Glioma  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2007 - 2012
  • Phase I/II Trial of Temozolomide and ABT-888 in Subjects with Newly Diagnosed  awarded by Johns Hopkins University 2010 - 2012
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^ 2009 - 2012
  • Private Grant  awarded by ASTRAZENECA INTERNATIONAL 2009 - 2011
  • A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2010 - 2011
  • Molecular Therapeutics for Anaplastic Gliomas - Core C  awarded by National Cancer Institute/NIH/DHHS 2005 - 2011
  • Post-Transcriptional Regulation Requires Phosphorylation of HuR in Gliomas  awarded by National Cancer Institute/NIH/DHHS 2006 - 2010
  • Private Grant  awarded by EMD PHARMACEUTICALS, INC. 2004 - 2010
  • Investigator On

  • Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients  awarded by BECKMAN RESEARCH INSTITUTE (CITY OF HOPE) 2020 - 2025
  • Private Grant  awarded by BLUE EARTH DIAGNONSTICS LTD ^ 2021 - 2025
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC. 2019 - 2024
  • Center for Clinical and Translational Science (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer  awarded by Johns Hopkins University 2018 - 2023
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2020 - 2023
  • NN106 Cytochrome C Oxidase Activity In Newly Diagnosed Glioblastoma Multiforme (GBM)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2016 - 2023
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease  awarded by Washington University 2013 - 2022
  • A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients with Recurrent Malignant Glioma  awarded by Gateway for Cancer Research (The) 2019 - 2022
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2021
  • Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients  awarded by National Cancer Institute/NIH/DHHS 2018 - 2021
  • Targeting PRMT5 in Cancer Initiating Cells as a New Therapy for Glioblastoma  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2021
  • Private Grant  awarded by SUMITOMO DIANIPPON PHARMA ONCOLOGY INC 2018 - 2021
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Integrating Basic Science And Community Outreach And Engagement To Bridge The Transdisciplinary Cancer Research Continuum  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Private Grant  awarded by MedImmune 2015 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Private Grant  awarded by ONCOCEUTICS INC 2019 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Radiation-Induced Crosstalk of Immune and Glioma Stem Cells  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2019 - 2020
  • A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma  awarded by National Cancer Institute/NIH/DHHS 2017 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Private Grant  awarded by VASCULAR BIOGENICS LTD 2016 - 2020
  • Decisional Capacity Evaluation in Metastatic Brain Cancer  awarded by American Cancer Society, Inc. 2015 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2019
  • Private Grant  awarded by BIOGEN, INC. 2016 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • The Frontotemporal Lobar Degeneration Clinical Research Consortium  awarded by University of California, San Francisco 2016 - 2019
  • Private Grant  awarded by IN8BIO INC. 2019
  • MARCKS as a Novel Regulator of Glioblastoma Growth and Treatment Resistance  awarded by American Cancer Society, Inc. 2014 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • SPRINT-MS: A Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis (NN 102)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2014 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)  awarded by University of Southern California 2017
  • Private Grant  awarded by Sanofi US Services Inc 2013 - 2017
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2015 - 2017
  • Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2  awarded by University of California, San Francisco 2015 - 2017
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Refinement and Expansion of the Palliative Care Research Cooperative Group (PCRC)  awarded by Duke University 2017
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of Southern California 2016 - 2017
  • Private Grant  awarded by NORTHWEST BIOTHERAPEUTICS 2015 - 2017
  • COMPLETED - Comprehensive Cancer Center Core Support Grant - Neuro-Oncology Program  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2015 - 2017
  • Private Grant  awarded by NOVOCURE (ISRAEL) LTD 2013 - 2016
  • Private Grant  awarded by GUERBET 2014 - 2016
  • Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II): A Phase III Randomized Multicenter Clinical Trail of Blood Pressure Reduction  awarded by University of Minnesota 2014 - 2016
  • Active - Major Program Leader - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by NOVOCURE, INC. 2014 - 2016
  • A Pilot Phase IIB, Randomized, Multi-Center Trial of Argatroban in Combination with Recombinant Tissue Plasminogen Activator for Acute Stroke (ARTSS-2)  awarded by UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER (HOUSTON) 2014 - 2015
  • UAB Center for Clinical and Translational Science (CCTS) (3 linked awards: UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2014 - 2015
  • Private Grant  awarded by BRACCO DIAGNOSTICS, INC. 2014 - 2015
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2014
  • UAB Center for Clinical and Translational Science (CCTS) UL1  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2011 - 2014
  • Private Grant  awarded by BRACCO DIAGNOSTICS, INC. 2012 - 2014
  • ACRIN 6684: Phase II Assessment of Tumor Hypoxia in Glioblastoma Using FMISO with PET and MRI (R09-185)  awarded by American College of Radiology 2010 - 2014
  • Private Grant  awarded by Sanofi US Services Inc 2010 - 2013
  • Molecular Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2004 - 2011
  • Education And Training

  • Doctor of Medicine, University of Tennessee System : Memphis 1991
  • National Naval Medical Center, Internship 1992
  • UAB Hospital, Residency 1998
  • National Naval Medical Center, Residency 1995
  • UAB Hospital, Postdoctoral Fellowship 1999
  • Full Name

  • Louis Nabors